Sign in
4

Changes in Ownership

Entrada Therapeutics, Inc. Filed Acc 0001689375-23-000061

Chief Operating Officer sold 972 shares at an average $13.47 ($13,089)

  • Chief Operating Officer gave up 436 shares (to pay taxes)
  • Chief Operating Officer acquired 14,200 shares (grant or award)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Dowden Nathan J Chief Operating Officer 2023-09-01 Grant or award 10b5-1 +14,200 49,576 D: show line 1 in the form
Dowden Nathan J Chief Operating Officer 2023-09-05 Shares withheld for taxes 10b5-1 −436 $14.46 $6,306 49,140 D: show line 2 in the form
Dowden Nathan J Chief Operating Officer 2023-09-06 Sale 10b5-1 −913 $13.43 $12,263 48,227 D: show line 3 in the form
Dowden Nathan J Chief Operating Officer 2023-09-06 Sale 10b5-1 −59 $14.01 $826 48,168 D: show line 4 in the form
Open-market sales · 972 sh · avg $13.47 · $13,089

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Dowden Nathan J Chief Operating Officer 2023-09-01 Grant or award · Stock Option (Right to Buy) 10b5-1 +21,500 21,500 D: show line 5 in the form
Loading xslF345X05/wf-form4_169403443743456.xml…